Van Cleef Asset Management Inc Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Van Cleef Asset Management Inc lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% in the first quarter, Holdings Channel reports. The institutional investor owned 120,941 shares of the biopharmaceutical company’s stock after selling 1,967 shares during the quarter. Gilead Sciences comprises about 1.8% of Van Cleef Asset Management Inc’s investment portfolio, making the stock its 17th biggest position. Van Cleef Asset Management Inc’s holdings in Gilead Sciences were worth $7,862,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc boosted its position in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after acquiring an additional 1,071,619 shares in the last quarter. Advisors Asset Management Inc. boosted its position in shares of Gilead Sciences by 45.5% during the 4th quarter. Advisors Asset Management Inc. now owns 91,175 shares of the biopharmaceutical company’s stock worth $5,703,000 after acquiring an additional 28,507 shares in the last quarter. Wilsey Asset Management Inc. boosted its position in shares of Gilead Sciences by 5.0% during the 4th quarter. Wilsey Asset Management Inc. now owns 127,143 shares of the biopharmaceutical company’s stock worth $7,880,000 after acquiring an additional 6,050 shares in the last quarter. Reliance Trust Co. of Delaware boosted its position in shares of Gilead Sciences by 19.0% during the 4th quarter. Reliance Trust Co. of Delaware now owns 3,389 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 540 shares in the last quarter. Finally, Baldwin Brothers Inc. MA boosted its position in shares of Gilead Sciences by 47.2% during the 4th quarter. Baldwin Brothers Inc. MA now owns 808 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 259 shares in the last quarter. Institutional investors own 78.78% of the company’s stock.

Gilead Sciences stock opened at $66.36 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $85.41 billion, a PE ratio of 10.79, a PEG ratio of 0.64 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The business had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the business earned $1.48 EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 6.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.80%. The ex-dividend date of this dividend is Thursday, June 13th. Gilead Sciences’s payout ratio is currently 40.98%.

Several research analysts have recently issued reports on GILD shares. Mizuho reaffirmed a “buy” rating and set a $88.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Thursday, March 7th. Piper Jaffray Companies set a $75.00 price objective on Gilead Sciences and gave the stock a “hold” rating in a research report on Thursday, March 7th. BMO Capital Markets started coverage on Gilead Sciences in a research report on Thursday, March 14th. They set an “outperform” rating and a $78.00 price objective for the company. Finally, Oppenheimer set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, March 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $79.54.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total value of $186,104.52. Following the sale, the director now directly owns 57,728 shares of the company’s stock, valued at $3,745,969.92. The disclosure for this sale can be found here. Insiders sold a total of 28,602 shares of company stock valued at $1,863,445 over the last three months. Company insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Van Cleef Asset Management Inc Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2019/06/15/van-cleef-asset-management-inc-cuts-stake-in-gilead-sciences-inc-nasdaqgild.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What Does a Sell-Side Analyst Rating Mean?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit